Key result
Higher CD4/CD8 ratio is linked to ~72% lower risk of cIMT progression in HIV.
Why the study?
Inversion of the CD4/CD8 ratio is a surrogate marker of immunosenescence and predictor of AIDS events and mortality, but its association with carotid intima-media thickness progression in treated HIV patients was unclear.
Cohort (n=96)
Odds Ratio: 0.283 (95% CI 0.099–0.809)
p-value: p=0.019
In virally suppressed HIV patients on antiretroviral therapy, an inverted CD4/CD8 ratio is independently associated with subclinical atherosclerosis progression, suggesting its potential utility as a predictor of cardiovascular events.
CD4/CD8 inversion was associated with cIMT progression in treated HIV; leaves open utility for cardiovascular risk stratification.
Inversion of the CD4/CD8 ratio (<1) has been identified as a surrogate marker of immunosenescence and an independent predictor of AIDS events in HIV-infected patients and mortality in the general population. We aimed to assess the association between the CD4/CD8 ratio and carotid intima-media thickness (cIMT) progression in treated HIV-infected patients as a marker of coronary heart disease. A longitudinal study was conducted during 3 years in 96 virally suppressed HIV-infected patients receiving antiretroviral treatment (ART). We analyzed the associations between the CD4/CD8 ratio, cardiovascular risk factors, and antiretroviral treatment (ART) and progression of subclinical atherosclerosis assessed using cIMT at baseline and after 3 years. Finally, 96 patients completed the study. Seventy six (79.1%) patients were male, aged 44 ± 10 years; 39 (40.6%) were on treatment with protease inhibitors; 49 (51.04%) with nonnucleoside reverse transcriptase inhibitors, 6 (6.25%) with integrase inhibitors, 3 (3.12%) with maraviroc, and 2 (2.08%) just with nucleoside reverse transcriptase inhibitors. The mean of ART exposition was 6.9 ± 5.9 years. Twenty six (27%) patients had family history of ischemic heart disease, 51 (53.12%) were smokers, 12 (12.5%) were hypertensive, 4 (4.16%) had type 2 diabetes, 23 (23.9%) had dyslipidemia, and 31 (32.3%) were infected with hepatitis C virus. Baseline cIMT was significantly associated with age (rho = 0.497; p < .001), basal glucemia (rho = 0.323; p = .001), triglycerides (rho = 0.232; p = .023), Framingham risk score (rho = 0.324; p = .001), CD4/CD8 ratio (rho = -0.176; p = .05), and dyslipidemia (0.72 ± 0.16 mm vs. 0.63 ± 0.11 mm; p = .029). In multivariable analysis where cardiovascular risk factor and ART were included, cIMT progression was inversely associated with CD4/CD8 ratio [odds ratio (OR) = 0.283; confidence interval (95% CI) 0.099-0.809; p = .019]. In conclusion, the inversion of CD4/CD8 ratio in treated HIV-infected patients is independently associated with cIMT progression, a marker of coronary heart disease. Therefore, it might be clinically useful as predictor of cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Bernal et al. (2016) conducted a cohort in HIV infection (n=96). CD4/CD8 ratio was evaluated on carotid intima-media thickness (cIMT) progression (OR 0.283, 95% CI 0.099-0.809, p=0.019). The CD4/CD8 ratio was inversely associated with carotid intima-media thickness progression in treated HIV-infected patients (OR 0.283; 95% CI 0.099-0.809; p=0.019).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: